Department of Oncological Sciences and Pharmacological Sciences, Center for Therapeutics Discovery, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
FEBS J. 2022 Mar;289(5):1256-1275. doi: 10.1111/febs.15844. Epub 2021 May 19.
PRDF1 and RIZ1 homology domain containing (PRDMs) are a subfamily of Krüppel-like zinc finger proteins controlling key processes in metazoan development and in cancer. PRDMs exhibit unique dualities: (a) PR domain/ZNF arrays-their structure combines a SET-like domain known as a PR domain, typically found in methyltransferases, with a variable array of C2H2 zinc fingers (ZNF) characteristic of DNA-binding transcription factors; (b) transcriptional activators/repressors-their physiological function is context- and cell-dependent; mechanistically, some PRDMs have a PKMT activity and directly catalyze histone lysine methylation, while others are rather pseudomethyltransferases and act by recruiting transcriptional cofactors; (c) oncogenes/tumor suppressors-their pathological function depends on the specific PRDM isoform expressed during tumorigenesis. This duality is well known as the 'Yin and Yang' of PRDMs and involves a complex regulation of alternative splicing or alternative promoter usage, to generate full-length or PR-deficient isoforms with opposing functions in cancer. In conclusion, once their dualities are fully appreciated, PRDMs represent a promising class of targets in oncology by virtue of their widespread upregulation across multiple tumor types and their somatic dispensability, conferring a broad therapeutic window and limited toxic side effects. The recent discovery of a first-in-class compound able to inhibit PRDM9 activity has paved the way for the identification of further small molecular inhibitors able to counteract PRDM oncogenic activity.
PRDF1 和 RIZ1 同源结构域包含物(PRDMs)是一类 Krüppel 样锌指蛋白亚家族,控制着后生动物发育和癌症中的关键过程。PRDMs 表现出独特的双重性:(a)PR 结构域/ZNF 结构域——其结构结合了一种 SET 样结构域,通常称为 PR 结构域,存在于甲基转移酶中,与可变的 C2H2 锌指(ZNF)阵列相结合,后者是 DNA 结合转录因子的特征;(b)转录激活剂/抑制剂——它们的生理功能依赖于上下文和细胞;在机制上,一些 PRDMs 具有 PKMT 活性,可直接催化组蛋白赖氨酸甲基化,而其他则是伪甲基转移酶,通过招募转录共因子发挥作用;(c)癌基因/肿瘤抑制基因——它们的病理功能取决于肿瘤发生过程中表达的特定 PRDM 同工型。这种双重性被称为 PRDMs 的“阴阳”,涉及到可变剪接或替代启动子使用的复杂调节,以产生具有相反功能的全长或 PR 缺失同工型,这些同工型在癌症中发挥作用。总之,一旦充分了解它们的双重性,PRDMs 就代表了肿瘤学中一个有前途的靶标类别,因为它们在多种肿瘤类型中广泛上调,并且具有体细胞非必需性,从而提供了广泛的治疗窗口和有限的毒副作用。最近发现了一种能够抑制 PRDM9 活性的首创化合物,为鉴定能够拮抗 PRDM 致癌活性的进一步小分子抑制剂铺平了道路。